Flag of the European Union EU Clinical Trials Register Help

Clinical trials for COPD

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    688 result(s) found for: COPD. Displaying page 1 of 35.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-001800-39 Sponsor Protocol Number: D3251C00014 Start Date*: 2019-11-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to V...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) BE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003797-30 Sponsor Protocol Number: D9180C00003 Start Date*: 2022-01-31
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) CZ (Trial now transitioned) BG (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002933-18 Sponsor Protocol Number: COPDIT Start Date*: 2007-11-05
    Sponsor Name:InfectoPharm Arzneimittel und Consilium GmbH
    Full Title: Multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase III-Studie zur (Langzeit-) Add On-Behandlung der COPD (Schweregrad III/IV) mit 2 x 80 mg inhalativem Tobramycin (Gernebcin)
    Medical condition: Austherapierte schwere bis sehr schwere COPD (Schweregrad III-IV) mit mindestens 2 COPD-Exazerbations-bedingten Hospitalisationen innerhalb der letzten 12 Monate
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019685-87 Sponsor Protocol Number: RO-2455-404-RD Start Date*: 2011-04-27
    Sponsor Name:Takeda Pharma A/S
    Full Title: Effect of roflumilast on exacerbation rate in patients with COPD treated with fixed combinations of LABA and ICS. A 52-week, randomised double-blind trial with roflumilast 500 μg versus placebo
    Medical condition: severe chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) AT (Completed) DK (Completed) GR (Completed) NL (Completed) HU (Completed) SK (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-004369-29 Sponsor Protocol Number: 206854 Start Date*: 2018-04-24
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGYTM ELLIPTATM) when Compared with Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-003253-28 Sponsor Protocol Number: MV130-SLG-001 Start Date*: 2012-12-13
    Sponsor Name:Inmunotek S.L.
    Full Title: Randomized double-blind placebo-controlled prospective, parallel, multicentre clinical trial of bacterial polivalent vaccine (BACTEK ®)administered by sublingual mucosa in subjects with chronic o...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-001053-16 Sponsor Protocol Number: D2550C00005 Start Date*: 2014-10-07
    Sponsor Name:AstraZeneca AB
    Full Title: A 12-week Phase IIa, Double-blind, Placebo-controlled, Randomized Study to Investigate the Efficacy and Safety of AZD7624 in COPD Patients with a History of Frequent Acute Exacerbations while on Ma...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-003937-42 Sponsor Protocol Number: BY217/M2-124 Start Date*: 2005-06-16
    Sponsor Name:ALTANA Pharma AG
    Full Title: Effect of roflumilast on exacerbation rate in patients with COPD A 52 weeks, double-blind study with 500 mcg roflumilast once daily versus placebo
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010952 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004966-16 Sponsor Protocol Number: CQVA149A2318 Start Date*: 2013-02-27
    Sponsor Name:Novartis Pharma AG
    Full Title: A 52-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) wit...
    Medical condition: subjects with moderate to very severe COPD
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) SE (Completed) ES (Completed) AT (Completed) LT (Completed) NL (Completed) CZ (Completed) FI (Completed) DE (Completed) BE (Completed) IS (Completed) IT (Completed) PT (Completed) NO (Completed) PL (Completed) EE (Completed) DK (Completed) BG (Completed) LV (Completed) GR (Completed) GB (Completed) LU (Completed)
    Trial results: View results
    EudraCT Number: 2019-001363-67 Sponsor Protocol Number: D5241C00001 Start Date*: 2019-10-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients with Moderate to Very Severe Chronic Obstru...
    Medical condition: Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NL (Completed) FR (Completed) DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2009-010084-16 Sponsor Protocol Number: 6645 Start Date*: 2009-07-24
    Sponsor Name:Barts Health NHS Trust
    Full Title: Randomised, Multi-Centre, Double-Blind, Placebo-Controlled Trial of Vitamin D Supplementation in Patients with Chronic Obstructive Pulmonary Disease
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004166-16 Sponsor Protocol Number: SimvaCOPD Start Date*: 2012-08-07
    Sponsor Name:Abteilung für Pulmologie, Landesklinikum Thermenregion Hochegg
    Full Title: Does simvastatin treatment affect COPD exacerbations? - Evaluation in a randomized controlled trial
    Medical condition: patients with COPD in stage II-IV (according to the GOLD classification)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    14.1 10021881 - Infections and infestations 10029978 Obstructive chronic bronchitis with acute exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004178-24 Sponsor Protocol Number: 1704 Start Date*: 2020-06-13
    Sponsor Name:Amphia
    Full Title: Defining long-term macrolide maintenance therapy in COPD: a single center randomized controlled trial:
    Medical condition: Chronic obstructive pulmonary disease COPD
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    21.1 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002952-17 Sponsor Protocol Number: COPDIron Start Date*: 2012-11-12
    Sponsor Name:University of Oxford
    Full Title: Effects of intravenous iron on hypoxic pulmonary responses in COPD
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004297-98 Sponsor Protocol Number: 117113 Start Date*: 2014-09-01
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study 117113: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil level.
    Medical condition: Treatment of severe Chronic Obstructive Pulmonary Disease (COPD) in patients presenting frequent exacerbations
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SK (Completed) DE (Completed) GB (Completed) DK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2018-004267-32 Sponsor Protocol Number: CQAW039E12201 Start Date*: 2019-04-10
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, proof-of-mechanism study of multiple, oral doses of fevipiprant (QAW039) in COPD patients with eosinophilia
    Medical condition: Chronic obstructive pulmonary disease with eosinophilia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003510-41 Sponsor Protocol Number: 200163 Start Date*: 2014-01-24
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A two part, Phase IIa, randomized, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of oral danirixin (GSK1325756) in symp...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005389-39 Sponsor Protocol Number: D2340C00011 Start Date*: 2012-03-12
    Sponsor Name:ASTRAZENECA
    Full Title: A phase-II, double-blind, placebo-controlled, randomised, parallelgroup, multi-centre study to assess the efficacy and safety of two staggered dose levels of inhaled once daily AZD5423 or twice d...
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SK (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-013256-69 Sponsor Protocol Number: CQVA149A2304 Start Date*: 2010-04-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 64-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and open-label tiotropi...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010952 COPD LLT
    12.1 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) FI (Completed) CZ (Completed) NL (Completed) SK (Completed) ES (Completed) GB (Completed) DK (Completed) FR (Completed) EE (Completed) IE (Completed) IT (Completed) PL (Completed) AT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2016-000155-28 Sponsor Protocol Number: PT009003 Start Date*: 2016-11-21
    Sponsor Name:Pearl Therapeutics, Inc. (Pearl)
    Full Title: A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 compared to PT005 in Subjects With Moderate to Very Severe COPD
    Medical condition: Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed) GB (Completed) DE (Completed) ES (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 08:43:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA